ReviewFrontiers in genetics2026
Multimodal biomarkers for early detection and immunotherapy assessment in hepatocellular carcinoma: integrating liquid biopsy, AI-based imaging and tumor immune profiling.
Review in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) commonly develops in chronically diseased liver and remains challenging because of late detection, heterogeneity, recurrence and limited hepatic reserve. Immune checkpoint inhibitor (ICI)-based combinations improve outcomes in advanced HCC, but durable responses occur in only a subset of patients. This structured narrative review evaluates biomarkers by intended use: surveillance and early detection, pretreatment prognostic stratification, treatment selection, on-treatment monitoring, neoadjuvant response assessment and postoperative minimal residual disease (MRD) detection. Serum alpha-fetoprotein and clinical scores are accessible but largely reflect tumor burden, inflammation or liver function. Cell-free DNA methylation and fragmentomics provide early-detection and tissue-of-origin signals, while circulating tumor DNA tracks molecular burden and clonal evolution. Tissue and spatial profiling clarify immune responsiveness and resistance, whereas radiomics and deep learning noninvasively assess whole-tumor and peritumoral heterogeneity. These modalities are complementary but require distinct evidence standards. Most early-detection studies use case-control or enriched cohorts, and most immunotherapy associations are retrospective, prognostic or monitoring-related. No biomarker yet supports routine selection among ICI regimens. Unlike modality-specific summaries, this review aligns each biomarker with a defined clinical decision and evidentiary category and proposes a longitudinal framework integrating baseline blood, imaging and tissue features with on-treatment dynamics, preoperative reassessment and postoperative molecular surveillance. Clinical translation requires standardized assays, representative multicenter cohorts, locked external validation and biomarker-guided trials demonstrating value beyond established criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.